Haleon (LON:HLN) Insider Acquires £24,850.80 in Stock

Haleon plc (LON:HLN) insider Blathnaid Bergin purchased 7,670 shares of Haleon stock in a transaction that occurred on Friday, October 30th. The shares were bought at an average cost of GBX 324 per share, for a total transaction of £24,850.80.

Haleon Stock Up 3.7%

LON HLN opened at GBX 337.60 on Thursday. The stock has a market cap of £29.69 billion, a PE ratio of 18.65, a P/E/G ratio of 1.49 and a beta of 0.24. Haleon plc has a fifty-two week low of GBX 310.50 and a fifty-two week high of GBX 433.60. The business has a 50 day moving average price of GBX 350.65 and a two-hundred day moving average price of GBX 359.86. The company has a quick ratio of 0.93, a current ratio of 0.69 and a debt-to-equity ratio of 50.38.

Haleon announced that its board has initiated a share repurchase plan on Thursday, October 29th that permits the company to buy back £500 million in outstanding shares. This buyback authorization permits the company to repurchase up to 1.8% of its shares through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

HLN has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of Haleon to a “hold” rating and decreased their target price for the company from GBX 320 to GBX 310 in a research note on Friday, October 30th. Royal Bank Of Canada raised their price target on shares of Haleon from GBX 370 to GBX 390 and gave the company a “sector perform” rating in a report on Tuesday, August 11th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 400 price target on shares of Haleon in a research note on Friday, October 30th. Finally, Berenberg Bank cut their price objective on shares of Haleon from GBX 514 to GBX 365 and set a “buy” rating on the stock in a report on Monday. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of GBX 356.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.